导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.41% | 3180/4773 |
| 近一周 | -4.81% | 5280/5467 |
| 近一月 | -7.01% | 3347/5421 |
| 近一季 | -10.13% | 3247/5238 |
| 近半年 | -11.87% | 3789/4931 |
| 近一年 | 16.13% | 680/4400 |
| 近两年 | 85.59% | 754/2954 |
| 近三年 | 49.20% | 560/2253 |
| 成立以来 | 70.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.61% 692/4961 |
-0.14% 3258/5312 |
- - |
- - |
| 2025 | 64.17% 157/4813 |
6.14% 674/3635 |
1.16% 2441/4076 |
33.90% 1026/4524 |
14.20% 93/4813 |
| 2024 | 3.15% 1940/3463 |
4.92% 418/2808 |
-3.33% 1347/3014 |
10.75% 2596/3129 |
-8.18% 2836/3463 |
| 2023 | -13.89% 1569/2656 |
3.70% 1145/2280 |
-9.66% 2060/2385 |
-2.22% 641/2515 |
-6.00% 1586/2655 |
| 2022 | -20.09% 932/2207 |
-10.57% 403/1919 |
5.40% 910/2016 |
-14.33% 1068/2113 |
-1.05% 1673/2208 |
| 2021 | 29.44% 74/1822 |
3.96% 164/1255 |
11.27% 384/1330 |
14.74% 81/1466 |
-2.48% 1411/1822 |
| 2020 | 28.75% 554/1250 |
-9.64% 702/1028 |
10.53% 764/1067 |
12.34% 392/1164 |
14.75% 249/1184 |
| 2019 | 25.32% 603/1092 |
27.40% 349/754 |
-6.59% 513/804 |
-5.02% 785/850 |
10.86% 92/918 |
| 2018 | -36.34% 588/834 |
- - |
- - |
- - |
-16.27% 630/691 |
| 2017 | 12.01% 286/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.62% 201/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发中证全指原材料ETF VS. 长安沪深300非周期A(740101) |